ZMYND8 drives HER2 antibody resistance in breast cancer via lipid control of IL-27
Cited by 9
Related Papers
Histone demethylase JMJD2C is a coactivator for hypoxia-inducible factor 1 that is required for breast cancer progression
|Proceedings of the National Academy of Sciences|2012|228
ZMYND8 acetylation mediates HIF-dependent breast cancer progression and metastasis
|Journal of Clinical Investigation|2018|181
p24A, a Type I Transmembrane Protein, Controls ARF1-dependent Resensitization of Protease-activated Receptor-2 by Influence on Receptor Trafficking
|Journal of Biological Chemistry|2007|63
Targeting BCAT1 Combined with α-Ketoglutarate Triggers Metabolic Synthetic Lethality in Glioblastoma
|Cancer Research|2022|56
ZMYND8 protects breast cancer stem cells against oxidative stress and ferroptosis through activation of NRF2
|Journal of Clinical Investigation|2024|51